AU2023345675A1 - Ngf for the treatment of spasticity - Google Patents

Ngf for the treatment of spasticity Download PDF

Info

Publication number
AU2023345675A1
AU2023345675A1 AU2023345675A AU2023345675A AU2023345675A1 AU 2023345675 A1 AU2023345675 A1 AU 2023345675A1 AU 2023345675 A AU2023345675 A AU 2023345675A AU 2023345675 A AU2023345675 A AU 2023345675A AU 2023345675 A1 AU2023345675 A1 AU 2023345675A1
Authority
AU
Australia
Prior art keywords
ngf
mutein
seq
tbi
spasticity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023345675A
Other languages
English (en)
Inventor
Marcello Allegretti
Andrea Aramini
Laura Brandolini
Franca Cattani
Flavio MANTELLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of AU2023345675A1 publication Critical patent/AU2023345675A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2023345675A 2022-09-23 2023-09-25 Ngf for the treatment of spasticity Pending AU2023345675A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22197562.6 2022-09-23
EP22197562.6A EP4342485A1 (en) 2022-09-23 2022-09-23 Ngf for the treatment of spasticity
PCT/EP2023/076387 WO2024062135A1 (en) 2022-09-23 2023-09-25 Ngf for the treatment of spasticity

Publications (1)

Publication Number Publication Date
AU2023345675A1 true AU2023345675A1 (en) 2025-03-06

Family

ID=83438536

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023345675A Pending AU2023345675A1 (en) 2022-09-23 2023-09-25 Ngf for the treatment of spasticity

Country Status (7)

Country Link
EP (2) EP4342485A1 (https=)
JP (1) JP2025532676A (https=)
CN (1) CN120239610A (https=)
AU (1) AU2023345675A1 (https=)
CA (1) CA3266315A1 (https=)
IL (1) IL319010A (https=)
WO (1) WO2024062135A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026022244A1 (en) 2024-07-23 2026-01-29 Chiesi Farmaceutici S.P.A. A polypeptide for use in the therapeutic management of acute ischaemic stroke

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
CN104203264B (zh) 2011-12-19 2018-08-28 瓦克化学有限公司 新型proNGF突变体及其在生产β-NGF中的用途
WO2017157325A1 (zh) * 2016-03-18 2017-09-21 舒泰神（北京）生物制药股份有限公司 神经生长因子融合蛋白、制备方法及其用途
IT201600112420A1 (it) * 2016-11-08 2018-05-08 Univ Cattolica Del Sacro Cuore Nuova formulazione per via intranasale
MA52351A (fr) 2018-04-27 2021-05-26 Chiesi Farm Spa Production du facteur de croissance nerveuse (ngf) et de mutéines de celui-ci
HRP20241431T1 (hr) * 2019-09-17 2024-12-20 Chiesi Farmaceutici S.P.A. Mutant ngf za upotrebu u liječenju ili prevenciji oftalmoloških poremećaja
CN114829384B (zh) * 2020-11-19 2023-12-12 舒泰神（北京）生物制药股份有限公司 长效神经生长因子多肽及其用途

Also Published As

Publication number Publication date
WO2024062135A1 (en) 2024-03-28
CA3266315A1 (en) 2024-03-28
CN120239610A (zh) 2025-07-01
EP4342485A1 (en) 2024-03-27
IL319010A (en) 2025-04-01
EP4590324A1 (en) 2025-07-30
JP2025532676A (ja) 2025-10-01

Similar Documents

Publication Publication Date Title
Zimmer et al. Effect of spinal cord injury on the respiratory system: basic research and current clinical treatment options
Kostich et al. Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain
JP2838073B2 (ja) 痛覚脱失を生じるためならびにニューロパシー性疼痛疾患の進行を阻害するための組成物および処方物
CN101288768A (zh) 用于治疗渐进神经退化症的医药组合物
KR102677904B1 (ko) 마그네슘-함유 옥시토신 제제 및 사용 방법
JP2007197463A (ja) 筋痙攣およびそれに関連する疼痛を除去するための注射療法
US20230226054A1 (en) Dry eye treatments
EP2679239A1 (de) Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
Goldshmit et al. Blood glutamate scavengers and exercises as an effective neuroprotective treatment in mice with spinal cord injury
AU2023345675A1 (en) Ngf for the treatment of spasticity
CA2516857A1 (en) Use of intraputaminal infused glial cell-line derived neurotrophic factor in the treatment of parkinson's disease in humans
IT201900002109A1 (it) Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale
Alvarez et al. Hippocampal histamine receptors: possible role on the mechanisms of memory in the rat, II
Kuntz et al. Effects of secretin on extracellular amino acid concentrations in rat hippocampus
US20060251649A1 (en) Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
Baca-Alonso et al. Neurotrophic effects of GH and GnRH in a full sciatic nerve transection model in male rats
US12246058B2 (en) Methods and compositions for treating pain
TWI902336B (zh) 二價金屬乳酸鹽在製備修復神經損傷之製品中的用途
KR20190142404A (ko) 보툴리눔 독소 및 히알루론산을 포함하는 족부통증 질환 치료용 약학적 조성물 및 이를 이용한 족부통증 질환 치료방법
Sapunar et al. Effect of peripheral axotomy on pain-related behavior and dorsal root ganglion neurons excitability in NPY transgenic rats
Nishino et al. Laryngeal inputs in defensive airway reflexes in humans
García del Barco et al. Therapeutic effect of the combined use of growth hormone releasing peptide-6 and epidermal growth factor in an axonopathy model
US20170143790A1 (en) Oxytocin improves treatment of obstructive sleep apnea
Smith et al. Effects of glycine administration on canine experimental spinal spasticity and the levels of glycine, glutamate, and aspartate in the lumbar spinal cord
Jordan Central nervous control of the airways